论文部分内容阅读
目的探讨左氧氟沙星联合阿莫西林克拉维酸钾治疗耐多药肺结核的临床疗效。方法将212例耐多药肺结核患者随机分为观察组和对照组各106例。所有患者均严格给予抗结核化疗,支持治疗和密切护理,观察组给予左氧氟沙星联合阿莫西林克拉维酸钾治疗,对照组仅给予左氧氟沙星治疗。治疗后观察2组临床疗效、病灶吸收程度、空洞闭合情况。结果观察组总有效率为95.28%高于对照组的83.02%,差异均有统计学意义(P<0.05)。观察组病灶吸收率、空洞闭合率均高于对照组,差异均有统计学意义(P<0.05)。结论左氧氟沙星联合阿莫西林克拉维酸钾治疗耐多药肺结核具有良好的治疗效果,且不增加不良反应事件发生率,值得临床推广应用。
Objective To investigate the clinical efficacy of levofloxacin combined with amoxicillin and clavulanate in the treatment of multidrug-resistant pulmonary tuberculosis. Methods 212 patients with multidrug-resistant pulmonary tuberculosis were randomly divided into observation group and control group, 106 cases each. All patients were given anti-TB chemotherapy, supportive care and close care. The observation group was treated with levofloxacin and amoxicillin-clavulanate potassium, while the control group was given levofloxacin only. After treatment, the clinical efficacy, the degree of lesion absorption and the cavity closure were observed. Results The total effective rate in the observation group was 95.28% higher than that in the control group (83.02%), the differences were statistically significant (P <0.05). Absorption rate and void closure rate of the observation group were higher than those of the control group, the difference was statistically significant (P <0.05). Conclusion Levofloxacin combined with amoxicillin and clavulanate potassium treatment of multidrug-resistant pulmonary tuberculosis has a good therapeutic effect, and does not increase the incidence of adverse reactions, worthy of clinical application.